Lessons from cholesterol-lowering trials

American Journal of Medicine

Volumn 104, Issue 6 A, 1998, Pages 28S-32S

  Smith Jr , Sidney C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; COLESTYRAMINE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; RESIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; LIFESTYLE; MORTALITY; PRIORITY JOURNAL; REVIEW;

EID: 0345367515     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(98)00185-5     Document Type: Review

References (20)

1. 1997 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 1997.
2. Castelli WP. Epidemiology of coronary heart disease: the Framingham Study. Am J Med. 1984;76:4-12.
3. Keys A. Coronary Heart Disease in Seven Countries. American Heart Association Monograph No. 29. Circulation. 1970;41(suppl I):I-1-I-14, I-186-I-196.
4. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982;248:1465-1477.
5. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
6. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
7. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation. 1996; 93:1796-1802.
8. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
9. Smith SC, Blair SN, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. Circulation. 1995;92:2-4.
10. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328-1428.
11. Tonkin A. Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Presented at the American Heart Association 70th Scientific Sessions; November 12, 1997; Orlando, FL.
12. The Post Coronary Artery Bypass Graft Trial investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162.
13. Herd JA, Ballantyne CM, Farmer JA, et al, for the LCAS investigators. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997;80:278-286.
14. Shepherd J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
15. Gotto AM Jr. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Presented at the American Heart Association 70th Scientific Sessions; November 12, 1997; Orlando, FL.
16. Brown MS, Goldstein JL. Heart attacks: gone with the century? (Editorial.) Science. 1996;272:629.
17. Sueta CA, Petkun WM, Lulla A, et al. Recommended management for hyperlipidemia and heart failure: are we following the guidelines? Circulation. 1997;96:I-66-I-67.
18. Grundy SM, Balady GJ, Criqui MH, et al. When to start cholesterol lowering therapy in patients with coronary heart disease: a statement for healthcare professionals from the American Heart Association task force on risk reduction. Circulation. 1997;95:1683-1685.
19. Smith SC, Thomas TS. Lipid lowering therapy and risk management: the role of a multidisciplinary team. ACC Current Journal Review. March/April 1997.
20. Debusk RF, Houston Miller N, Superko R, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 1994; 120:721-729.